- Home
- OVID vs XGN Comparison
OVID vs XGN Comparison
Compare OVID & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | XGN |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 110.8M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OVID | XGN |
|---|---|---|
| Price | $1.60 | $3.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $3.40 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.7M | 765.1K |
| Earning Date | 03-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,610,000.00 | ★ $63,599,000.00 |
| Revenue This Year | $1,077.56 | $21.40 |
| Revenue Next Year | N/A | $14.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 945.89 | 14.08 |
| 52 Week Low | $0.24 | $2.67 |
| 52 Week High | $2.01 | $12.23 |
Technical Indicators
Market Signals| Indicator | OVID | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 20.43 |
| Support Level | $1.40 | $3.32 |
| Resistance Level | $1.61 | $4.01 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 15.91 | 6.36 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.